Es gab 50 kürzliche Insider-Transaktionen für Atrium Therapeutics, Inc. (RNA), darunter 17 Käufe und 29 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $16.86M und die gesamten Insider-Verkäufe auf $8.27M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Gallagher Kathleen P., Flanagan W. Michael, Levin Arthur A. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — RNA
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2025-06-17 |
Gallagher Kathleen P. |
Chief Program Officer |
Informierter Verkauf |
911 |
$30.24 |
$27.55K |
50,392 |
| 2025-06-11 |
Flanagan W. Michael |
Chief Scientific Officer |
Informierter Verkauf |
20,000 |
$32.88 |
$657.69K |
80,195 |
| 2025-06-10 |
Levin Arthur A |
Director |
RSU-Zuteilung |
10,034 |
$33.62 |
$337.34K |
10,034 |
| 2025-06-10 |
Boess Carsten |
Director |
RSU-Zuteilung |
6,692 |
- |
- |
6,692 |
| 2025-06-10 |
Kaye Edward M. Md |
Director |
RSU-Zuteilung |
6,692 |
- |
- |
6,692 |
| 2025-06-10 |
Wilson Troy Edward |
Director |
RSU-Zuteilung |
10,034 |
$33.62 |
$337.34K |
10,034 |
| 2025-06-10 |
Henig Noreen |
Director |
RSU-Zuteilung |
6,692 |
- |
- |
6,692 |
| 2025-06-10 |
Thompson Tamar |
Director |
RSU-Zuteilung |
6,692 |
- |
- |
6,692 |
| 2025-06-10 |
Kim Jean Jinsun |
Director |
RSU-Zuteilung |
6,692 |
- |
- |
6,692 |
| 2025-06-10 |
Skerjanec Simona |
Director |
RSU-Zuteilung |
6,692 |
- |
- |
6,692 |
| 2025-06-02 |
Gallagher Kathleen P. |
Chief Program Officer |
Optionsausübung (Verkauf) |
5,875 |
$16.65 |
$97.82K |
22,596 |
| 2025-05-01 |
Gallagher Kathleen P. |
Chief Program Officer |
Optionsausübung (Verkauf) |
5,875 |
$16.65 |
$97.82K |
28,471 |
| 2025-04-01 |
Gallagher Kathleen P. |
Chief Program Officer |
Optionsausübung (Verkauf) |
5,546 |
$14.70 |
$81.53K |
13,829 |
| 2025-03-20 |
Maclean Michael F |
Chief Financial Officer |
Informierter Verkauf |
7,935 |
$31.06 |
$246.42K |
96,720 |
| 2025-03-20 |
Boyce Sarah |
President and CEO |
Informierter Verkauf |
31,540 |
$31.06 |
$979.56K |
305,871 |
| 2025-03-20 |
Hughes Steven George |
Chief Medical Officer |
Informierter Verkauf |
9,578 |
$31.06 |
$297.49K |
72,850 |
| 2025-03-20 |
Flanagan W. Michael |
Chief Scientific Officer |
Informierter Verkauf |
11,780 |
$31.06 |
$365.87K |
80,195 |
| 2025-03-20 |
Mccarthy Teresa |
Chief Human Resources Officer |
Informierter Verkauf |
7,778 |
$31.06 |
$241.58K |
97,130 |
| 2025-03-11 |
Flanagan W. Michael |
Chief Scientific Officer |
Informierter Verkauf |
20,000 |
$30.13 |
$602.61K |
91,975 |
| 2025-03-03 |
Gallagher Kathleen P. |
Chief Program Officer |
Optionsausübung (Verkauf) |
5,875 |
$14.70 |
$86.36K |
19,375 |
| 2025-02-03 |
Gallagher Kathleen P. |
Chief Program Officer |
Optionsausübung (Verkauf) |
5,875 |
$16.65 |
$97.82K |
34,675 |
| 2025-01-22 |
Gallagher Kathleen P. |
Chief Program Officer |
Informierter Verkauf |
5,629 |
$30.16 |
$169.78K |
50,554 |
| 2025-01-21 |
Levin Arthur A |
Director |
Informierter Verkauf |
1,872 |
$28.60 |
$53.54K |
12,958 |
| 2025-01-21 |
Maclean Michael F |
Chief Financial Officer |
Informierter Verkauf |
1,665 |
$28.59 |
$47.61K |
104,655 |
| 2025-01-21 |
Boyce Sarah |
President and CEO |
Informierter Verkauf |
5,659 |
$28.59 |
$161.82K |
337,411 |
| 2025-01-21 |
Hughes Steven George |
Chief Medical Officer |
Informierter Verkauf |
2,032 |
$28.59 |
$58.1K |
82,428 |
| 2025-01-21 |
Flanagan W. Michael |
Chief Scientific Officer |
Informierter Verkauf |
1,812 |
$28.59 |
$51.81K |
91,975 |
| 2025-01-21 |
Mccarthy Teresa |
Chief Human Resources Officer |
Informierter Verkauf |
1,221 |
$28.60 |
$34.92K |
104,908 |
| 2025-01-21 |
Gallagher Kathleen P. |
Chief Program Officer |
Informierter Verkauf |
1,817 |
$28.59 |
$51.95K |
56,183 |
| 2025-01-06 |
Maclean Michael F |
Chief Financial Officer |
RSU-Zuteilung |
50,000 |
$31.42 |
$1.57M |
50,000 |
| 2025-01-06 |
Moriarty John B |
Chief Legal Officer |
RSU-Zuteilung |
50,000 |
$31.42 |
$1.57M |
50,000 |
| 2025-01-06 |
Boyce Sarah |
President and CEO |
RSU-Zuteilung |
165,000 |
$31.42 |
$5.18M |
165,000 |
| 2025-01-06 |
Mosbrooker Eric |
Chief Commercial Officer |
Unbekannt |
315,000 |
$9.05 |
$2.85M |
- |
| 2025-01-06 |
Mosbrooker Eric |
Chief Commercial Officer |
RSU-Zuteilung |
50,000 |
$31.42 |
$1.57M |
50,000 |
| 2025-01-06 |
Hughes Steven George |
Chief Medical Officer |
Unbekannt |
84,625 |
$15.96 |
$1.35M |
- |
| 2025-01-06 |
Hughes Steven George |
Chief Medical Officer |
RSU-Zuteilung |
50,000 |
$31.42 |
$1.57M |
50,000 |
| 2025-01-06 |
Flanagan W. Michael |
Chief Scientific Officer |
RSU-Zuteilung |
50,000 |
$31.42 |
$1.57M |
50,000 |
| 2025-01-06 |
Mccarthy Teresa |
Chief Human Resources Officer |
RSU-Zuteilung |
50,000 |
$31.42 |
$1.57M |
50,000 |
| 2025-01-06 |
Gallagher Kathleen P. |
Chief Program Officer |
Unbekannt |
16,000 |
$44.00 |
$704K |
- |
| 2025-01-06 |
Gallagher Kathleen P. |
Chief Program Officer |
RSU-Zuteilung |
50,000 |
$31.42 |
$1.57M |
50,000 |
| 2025-01-06 |
Calderaro Charles Iii |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2025-01-06 |
Calderaro Charles Iii |
Chief Technical Officer |
RSU-Zuteilung |
40,000 |
- |
- |
40,000 |
| 2024-12-18 |
Maclean Michael F |
Chief Financial Officer |
Informierter Verkauf |
11,151 |
$32.66 |
$364.19K |
82,942 |
| 2024-12-18 |
Boyce Sarah |
President and CEO |
Informierter Verkauf |
31,855 |
$32.66 |
$1.04M |
265,308 |
| 2024-12-18 |
Flanagan W. Michael |
Csto |
Informierter Verkauf |
12,742 |
$32.66 |
$416.15K |
72,647 |
| 2024-12-18 |
Mccarthy Teresa |
Chief Human Resources Officer |
Informierter Verkauf |
11,151 |
$32.66 |
$364.19K |
82,867 |
| 2024-12-16 |
Mccarthy Teresa |
Chief Human Resources Officer |
Optionsausübung (Verkauf) |
25,000 |
$14.22 |
$355.5K |
57,500 |
| 2024-12-11 |
Flanagan W. Michael |
Csto |
Informierter Verkauf |
24,000 |
$35.77 |
$858.4K |
85,389 |
| 2024-11-19 |
Levin Arthur A |
Director |
Optionsausübung (Verkauf) |
3,323 |
$1.24 |
$4.12K |
- |
| 2024-11-18 |
Mccarthy Teresa |
Chief Human Resources Officer |
Optionsausübung (Verkauf) |
25,000 |
$14.22 |
$355.5K |
82,500 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
